

Syngene releases its first ESG report for FY2020-21 in accordance with the Global Reporting Initiative (GRI)

Bangalore, 24 February 2022: Syngene International, an integrated research, development and manufacturing services company, today announced the publication of its first Environmental, Social and Governance (ESG) Report for FY2020-21, aligned to the Global Reporting Initiative (GRI). The report measures progress on the company's key ESG priorities: health & safety; managing and minimizing the environmental footprint of operations; building a strong and motivated workforce; sustaining communities; and corporate governance.

Jonathan Hunt, Managing Director and Chief Executive Officer said, "Syngene is building on more than twenty years of responsible growth in which we have closely monitored and managed our operations and our impact on society and the planet. We firmly believe that responsible business is good business and this philosophy is reflected in the ESG priorities outlined in the report published today.

In the financial year to March 2021, we continued to implement initiatives to further enhance the environmental and social performance of our operations while delivering science that results in materials and medicines to improve the lives of people and patients."

"We are committed to making progress on our ESG priorities in the years to come for the benefit of our employees, customers, business partners, shareholders and communities." Hunt added.

Highlights of the ESG report: April 2020 - March 2021

- 82% procurement of electricity from green sources: 53,280 tCO₂ greenhouse gas emissions avoided
- 80% of total hazardous and non-hazardous waste recycled
- 550,190 kWh of total energy savings compared to the prior year
- 21% reduction in freshwater usage as a result of water conservation activities
- 24% share of female employees in the permanent workforce
- Introduced Switch On - a personal risk awareness program to help employees behave safely at home and at work

The Company's ESG priorities were derived after collecting feedback from a range of stakeholders to identify areas that could have a material impact on the company. These priority areas will provide the focus for structured planning to mitigate risks and provide a positive environment for business growth and the delivery of shared value to stakeholders.

The ESG strategy is driven by an Executive ESG Council chaired by the MD and CEO and includes the Chief Financial Officer and other members of the executive team. This committee ensures that ESG concerns are considered in all significant business decisions. The Stakeholders

Relationship and ESG Committee of the Syngene Board provides oversight on behalf of shareholders.

About Syngene International:

About Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022) is an integrated research, development and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical sectors. 'Syngene's more than 4700 scientists offer both skills and the capacity to deliver great science; robust data management and IP security; and quality manufacturing at speed to improve time-to-market and lower the cost of innovation. With a combination of dedicated research facilities for Amgen, Baxter and Bristol-Myers Squibb, as well as 2 Mn sq. ft of specialist discovery, development and manufacturing facilities, Syngene works with biotech companies pursuing leading-edge science as well as multinationals, including GSK and Merck KGaA. For more details, visit www.syngeneintl.com

Contact Details:	
GCI Health India Jeanelle Rodrigues M: +91 8976810587 Jeanelle.Rodrigues@gcihealth.com	Syngene International Shotorupa Ghosh M: +91 8450977080 Shotorupa.ghosh@syngeneintl.com